Cancer news - the latest biotech news from Labiotech.eu

Home Cancer Page 85

Latest Posts

buesa oryzon fil scaled

Interview 23 Mar 2017

Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics

Located right here in Barcelona, Oryzon is one of the world’s few epigenetics biotechs. I sat down with CEO Carlos Buesa to talk about its approach. Since its foundation in 2000, Oryzon has gone on to become the leader in epigenetic medicine and focuses on oncology. Most recently, the company announced the success of its lead […]

March 23, 2017 - 2 minutesmins - By Evelyn Warner

C7XeJ78WkAEE Ic 1.jpg large e1490029653662

Interview 20 Mar 2017

Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed

The unprecedented competition in the field represents a daunting challenge for companies trying to break in. A BIO-Europe Panel discussed remaining niches. BIO Europe’s panel on immuno-oncology was perhaps the most popular of the day, as attendees filled the room to hear the thoughts of John Haurum, CEO of F-star; Christophe Quéva, CSO of iTeos; and […]

March 20, 2017 - 3 minutesmins - By Evelyn Warner

David Sourdive Cellectis interview off the shelf cell therapy 1

Interview 16 Mar 2017

“In the Coming Decade, Off-the-Shelf Cell Therapy will Become a Reality”

David Sourdive, co-founder of Cellectis, discusses his pioneering work developing off-the-shelf CAR-T for cancer and the future directions of cell therapy. Last week I had the opportunity to attend the World ADOPT Summit and hear from some of the world leaders in cell therapy. There I met David Sourdive, co-founder and EVP Technical Operations at Cellectis, […]

March 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

shutterstock 587928761

Interview 6 Mar 2017

How did this Biotech seal a €1B Deal with AstraZeneca? The CEO Explains

We talked to the CEO of Bicycle Therapeutics, Kevin Lee, about how his company’s technology could cure not just cancer but also a raft of other diseases. Bicycle Therapeutics made a splashy debut in 2014 with a €25M fundraising round, only to outdo it with a €1B deal with AstraZeneca last fall. What’s the fuss? […]

March 6, 2017 - 7 minutesmins - By Evelyn Warner

shutterstock 569237143 3

News and Trends 2 Mar 2017

There’s a New Record in Biotech Fundraising: Should We Believe the Hype?

Illumina’s cancer diagnostics baby, GRAIL, has raked in a jaw-dropping $1B in Series B. Should Europe get on America’s level? A new genome sequencing company spun out of Illumina, GRAIL, has raised over $900M in a Series B fundraising round. That’s far and away the largest round ever; further, that’s more than most companies hope to be worth, […]

March 2, 2017 - 5 minutesmins - By Evelyn Warner

shutterstock 548463310

News and Trends 24 Feb 2017

What are the Current Challenges in the Booming Field of ADCs?

ADCs are overcoming the challenges of first generations and returning with a vengeance. I attended the World ADC Conference to hear about current efforts. ADCs represent an exciting new field that has seen renewed interest in the past few months, as funding has poured into NBE Therapeutics and ADC Therapeutics. Theses drugs are overcoming the challenges that held the first two generations back […]

February 24, 2017 - 5 minutesmins - By Evelyn Warner

ADVERTISEMENT

FullSizeRender 1

News and Trends 23 Feb 2017

In the Age of Biological Therapeutics, Chemists move to ADCs

Career options for chemists are shrinking in the shift towards biological drugs. But as antibody-drug conjugates (ADCs) take off, so do opportunities for chemists! Since I quit graduate school in chemistry research and dove into biotech journalism, I wasn’t sure when I would next enter a discussion about organic synthesis. This week, less than a year after […]

February 23, 2017 - 4 minutesmins - By Evelyn Warner

Celltrion Truxima EMA Approval

News and Trends 23 Feb 2017

Biosimilars set to take on Oncology after a new Market Authorization

The European Commission has approved Truxima, the world’s first biosimilar monoclonal antibody (mAb) with an oncology indication. Based in South Korea, Celltrion Healthcare is setting foot in the European oncology market with the approval of Truxima, a biosimilar to Roche’s Mabthera (rituximab). The European Commission has approved the antibody for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis […]

February 23, 2017 - 3 minutesmins - By Melanie De Almeida

cell medica immunotherapy cmd 003 ebv

News and Trends 21 Feb 2017

New Immunotherapy Candidate receives FDA Fast Track Designation

Cell Medica’s Orphan Drug CMD-003 has received fast track designation by the FDA to advance immunotherapy of patients with Epstein Bar Virus (EBV)-associated malignancies. The FDA’s fast track designation has been designed to facilitate and accelerate the development of drugs which fill a major unmet medical need. It has now been granted to Cell Medica’s lead EBV immunotherapy […]

February 21, 2017 - 3 minutesmins - By Melanie De Almeida

centauri therapeutics fundraising alphamer anti infective e1487589778369

News and Trends 20 Feb 2017

Alphamer Technology gets Seed Fundraising to Fight Antibiotic Resistance

Centauri Therapeutics has raised £1.2M in the second part of its seed round, which will be directed at bringing its first alphamer to the preclinical stage. Centauri Therapeutics, a young British biotech, is developing alphamer technology to fights infectious disease and cancer. Today, the company has announced the addition of £1.2M from existing and new investors […]

February 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Agor2012

Infographics 13 Feb 2017

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is […]

February 13, 2017 - 2 minutesmins - By Evelyn Warner

gw pharmaceuticals brain tumor cannabinoid

News and Trends 7 Feb 2017

Cannabinoid Drug Prolongs the Life of Brain Tumor Patients in Phase II Trials

GW Pharmaceuticals announced Phase II results for a cannabinoid drug combination with the potential to increase life expectancy in patients with an aggressive form of brain cancer. GW Pharmaceuticals, one of the coolest biotechs in Cambridge, is developing cannabinoid drugs. Its lead candidate, Epidiolex, could reach the market soon and help treat drug-resistant forms of […]

February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT